Report Open Access
Isabelle Boutron; Anna Chaimani; Joerg J Meerpohl; Asbjørn Hróbjartsson; Declan Devane; Gabriel Rada; David Tovey; Giacomo Grasselli; Philippe Ravaud
WHO declared COVID-19 a pandemic on March 11, 2020. Researchers are working to accelerate the development of diagnostic tests, preventive interventions and therapeutic interventions. Many randomized trials have been established to evaluate candidate therapeutic agents that may effectively reduce symptoms and avoid deaths. This emerging situation requires the optimal planning and conduct of trials as well as strategies for the appropriate translation of research into practice. Therefore, decision-makers and researchers urgently need a complete, high-quality and up-to-date synthesis of data from all ongoing research studies as soon as they are available.
To this end, we will perform a living mapping of registered randomized trials and a living systematic review with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: 1) the effectiveness of preventive interventions for COVID-19 and 2) the effectiveness of treatment interventions for COVID-19. We will evaluate the impact of these treatments considering the severity of the disease (i.e., mild, moderate, severe and critical diseases).
This protocol details the process and methods we will use.
Covid-NMA Cochrane master protocol_0809.docx
|All versions||This version|
|Data volume||3.6 GB||37.1 MB|